成人 0-1-2 个月和 0-1-6 个月 HBV 疫苗接种计划之间的两年免疫

StephenW

成人 0-1-2 个月和 0-1-6 个月 HBV 疫苗接种计划之间的两年免疫效果差异

    王娟、刘长海、马元吉、朱霞、罗丽茹、纪玉林、唐红

BMC传染病第22卷，文章编号：159（2022）引用这篇文章

    指标详情

抽象的
背景

短期 0-1-2 个月的乙型肝炎病毒 (HBV) 疫苗接种计划以前在成年人群中实施；然而，其长期免疫作用仍不清楚。本研究旨在调查 (1) HBV 疫苗接种的 2 个月和 2 年免疫效果，以及 (2) 成人 0-1-2 个月和 0-1-6 个月疫苗接种计划之间的依从率.
方法

共招募了 1281 名接受乙型肝炎表面抗原 HBsAg(-) 和乙型肝炎表面抗体 (anti-HBs)(-) 检测的受试者。来自两个遥远县的参与者接种了每剂 10 µg 的乙型肝炎酵母疫苗，疫苗接种时间为 0、1 和 2 个月（n = 606）和 0、1 和 6 个月（n = 675）；在第 3 次注射后 2 个月和 2 年进行序贯随访。
结果

在 2 个月时，0-1-2 个月和 0-1-6 个月疫苗接种计划组的抗 HBs 血清转化率无显着差异（91.96% vs. 89.42%，p = 0.229）和 2 年（81.06% 对 77.14%，p = 0.217）。 0-1-2 个月接种计划组的定量抗 HBs 水平与 0-1-6 个月接种计划组在 2 个月时的定量抗 HBs 水平（抗 HBs1）没有差异（342.12 ± 378.42 mIU/ml vs. 392.38 ± 391.96 mIU/ml，p = 0.062），但在 2 年时更高（抗 HBs2）（198.37 ± 286.44 mIU/ml vs. 155.65 ± 271.73 mIU/ml，p = ） .根据亚组分析，与 0-1-6 个月的疫苗接种计划相比，0-1-2 个月的疫苗接种计划产生了更好的维持（p = 0.041）和更长的强化（p = 0.019）。 0-1-2 个月疫苗接种计划组的第 3 次注射完成率也较高（89.49% 对 84.49%，p = 0.010）。
结论

0-1-2 个月的疫苗接种计划与类似的短期免疫效应相关，并可能在成年人群中诱导更好的长期免疫记忆和更高的完成率。

StephenW

Two-year immune effect differences between the 0–1–2-month and 0–1–6-month HBV vaccination schedule in adults

    Juan Wang, Chang-Hai Liu, Yuanji Ma, Xia Zhu, Liru Luo, Yulin Ji & Hong Tang

BMC Infectious Diseases volume 22, Article number: 159 (2022) Cite this article

    Metrics details

Abstract
Background

The short-term 0–1–2-month hepatitis B virus (HBV) vaccination schedule was previously implemented in the adult population; however, its long-term immune effect remains unclear. The present study aimed to investigate (1) the 2-month and 2-year immune effects of HBV vaccination and (2) the compliance rate between the 0–1–2-month and 0–1–6-month vaccination schedules in adults.
Method

A total of 1281 subjects tested for hepatitis B surface antigen HBsAg(−) and hepatitis B surface antibody (anti-HBs)(−) were recruited. Participants from two distant counties were inoculated with the hepatitis B yeast vaccine at 10 µg per dose, with vaccination schedules of 0, 1, and 2 months (n = 606) and 0, 1, and 6 months (n = 675); sequential follow-up was performed at 2 months and 2 years after the 3rd injection.
Results

There were no significant differences in the anti-HBs seroconversion rates between the those in the 0–1–2-month and 0–1–6-month vaccination schedule groups at 2 months (91.96% vs. 89.42%, p = 0.229) and 2 years (81.06% vs. 77.14%, p = 0.217). The quantitative anti-HBs level in those in the 0–1–2-month vaccination schedule group was not different from that in those in the 0–1–6-month vaccination schedule group at 2 months (anti-HBs1) (342.12 ± 378.42 mIU/ml vs. 392.38 ± 391.96 mIU/ml, p = 0.062), but it was higher at 2 years (anti-HBs2) (198.37 ± 286.44 mIU/ml vs. 155.65 ± 271.73 mIU/ml, p = 0.048). According to the subgroup analysis, the 0–1–2-month vaccination schedule induced better maintenance (p = 0.041) and longer reinforcement (p = 0.019) than the 0–1–6 vaccination schedule. The 0–1–2-month vaccination schedule group also had a higher 3rd injection completion rate (89.49% vs. 84.49%, p = 0.010).
Conclusion

The 0–1–2-month vaccination schedule was associated with a similar short-term immune effect and might induce better long-term immune memory and a higher completion rate in the adult population.

StephenW

https://bmcinfectdis.biomedcentr ... 879-022-07151-6.pdf